Open AccessGlucocorticoids delay RAF-induced senescence promoted by EGR1
Author(s) -
Cyril Carvalho,
Valentin L’Hôte,
Régis Courbeyrette,
Gueorgui Kratassiouk,
Guillaume Pinna,
JeanChristophe Cintrat,
Cyril Denby Wilkes,
Céline Derbois,
Robert Olaso,
JeanFrançois Deleuze,
Carl Mann,
JeanYves Thuret
Publication year - 2019
Publication title -
journal of cell science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.384
H-Index - 278
eISSN - 1477-9137
pISSN - 0021-9533
DOI - 10.1242/jcs.230748
Subject(s) - biology , egr1 , senescence , cancer research , mapk/erk pathway , transcription factor , microbiology and biotechnology , oncogene , kinase , transcriptome , gene expression , gene , cell cycle , genetics
Expression of hyper-active RAF kinases, such as the oncogenic B-RAF-V600E mutant, in normal human cells triggers a proliferative arrest that blocks tumor formation. We discovered that glucocorticoids delay the entry into senescence induced by B-RAF-V600E in human fibroblasts, and allow bypass when the cells are regularly passaged, but they do not allow proliferation of cells that were already senescent. Transcriptome and siRNA analyses revealed that the EGR1 gene is one target of glucocorticoid action. Transcription of the EGR1 gene is activated by the RAF-MEK-ERK MAP kinase pathway and acts as a sensor of hyper-mitogenic pathway activity. The EGR1 transcription factor regulates the expression of p15-CDKN2B and p21-CDKN1A that are redundantly required for the proliferative arrest of BJ fibroblasts upon expression of B-RAF-V600E. Our results highlight the need to evaluate glucocorticoid action on cancer progression in melanoma, thyroid and colon carcinoma in which B-RAF-V600E is a frequent oncogene, and cancers in which evasion from senescence has been shown.